Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle c - Wikidata - awgldk - TriplyDB

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle c

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle c

http://www.wikidata.org/entity/Q33372106

about

Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults Bendamustine for patients with B cell lymphoid malignancies Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Databa Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting.Endoscopic features and prognoses of mantle cell lymphoma with gastrointestinal involvement Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points Initial therapy of mantle cell lymphoma Activation of the Constitutive Androstane Receptor Increases the Therapeutic Index of CHOP in Lymphoma Treatment The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma First-line treatment of follicular lymphoma: a patient-oriented algorithm.Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma.Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis.Managing newly diagnosed follicular lymphoma: state of the art and future perspectives.Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group.Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation.Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective.Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies.Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options.Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma.Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL.Novel therapy for therapy-resistant mantle cell lymphoma: multipronged approach with targeting of hedgehog signaling.Follicular dendritic cells in follicular lymphoma and types of non-Hodgkin lymphoma show reduced expression of CD23, CD35 and CD54 but no association with clinical outcome.Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus.Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma.The G protein-coupled estrogen receptor 1 (GPER-1) contributes to the proliferation and survival of mantle cell lymphoma cells.Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD.ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma.Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma.FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma.

P2860

Q24200280-03B84E61-8DC3-4790-BAD3-373808601B11 Q24203878-EB034A09-576D-4CA7-A793-70B008332B8A Q24236426-D84ADD7C-8154-447D-AEDC-A9FF4D52356B Q30649483-7B71C3B3-370C-484F-BB42-7AA6B0477EDF Q33586239-3FD37B38-2EA9-4D25-8FD5-A75A2A7EFAD1 Q34095625-509E3B79-C0F6-489A-8EA1-67B2C6D12EA2 Q34183167-17A9C3D0-8ACD-4BD6-AD04-C13B54FC3BB6 Q35004750-79AD79C0-28E9-43D5-AB10-E350909FA612 Q36612648-A2C16C8E-1C17-4029-950B-6F82B4356E4F Q36665092-219CC8AC-DC89-4290-93E3-395CDD9ABCED Q37183720-A237B73C-3169-4528-AA05-6BA777435662 Q37396916-0B8227E6-1908-4F62-ACF6-98D8DDD6BCF8 Q37402853-5C222174-E07B-430C-8F81-E500C47AC5DA Q37498829-4F65546C-E032-420D-A7A8-FD5CBE6BBAA5 Q37728866-6739E4AF-D5FF-47BC-ABD2-5A096652926B Q37970668-19D34AAA-2AD6-49F6-B97E-9ADB05D3FF00 Q38088002-2A052615-695F-4BC9-8873-480014241635 Q38110232-32936222-7B67-4770-9F12-F9BB742D0BF4 Q38160456-7BB6CFFC-56CE-4FA6-9BB9-62049B9C5B84 Q38216650-3927EA01-B95F-41B8-8DC4-8ABE724317A1 Q38574045-259474FD-571B-489C-86E9-1CD69DC66BE6 Q38594531-E3BEE3C5-03CD-46D4-8435-A4A1A1C048B8 Q38711166-8A43B4DF-BF9C-4010-A261-E4F61C568B51 Q38818397-A199BE57-EC33-44C7-99E9-4452BAA6E399 Q39363109-25FEE7B4-13C0-461A-8925-0F1D9DA0B631 Q39974868-855F74AE-244D-4575-A8AA-C1F4EE049ABF Q41085672-BFED6287-11E6-421A-8812-C8D394B167D0 Q42284554-97819D8A-C006-462D-B416-E5B19D4A5473 Q42910841-8AD75A44-477B-4BBB-AB6F-E5411CDCD3DF Q44872919-03E01003-049D-4707-8496-6589342B7FBB Q45124918-9FF0B748-0BC5-49B4-A0D9-EE3E3F24A076 Q45951618-F5101866-3279-4512-BA58-7A6DBE90264A Q46830943-0B8D23F7-DABD-4DF6-AE9D-110950DDC51C Q47141499-731FE787-2158-4C43-89FD-C1B659C6F546 Q47419522-21DEDF66-86A4-4528-94F6-708AA3B557E3 Q51146815-8AE0B29A-A602-42BF-ADC9-7F017DC95D4B

P2860

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle c

http://www.wikidata.org/entity/Q33372106

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Combined cyclophosphamide, vin ...... CP) in follicular and mantle c

@ast

Combined cyclophosphamide, vin ...... CP) in follicular and mantle c

@en

type

label

Combined cyclophosphamide, vin ...... CP) in follicular and mantle c

@ast

Combined cyclophosphamide, vin ...... CP) in follicular and mantle c

@en

prefLabel

Combined cyclophosphamide, vin ...... CP) in follicular and mantle c

@ast

Combined cyclophosphamide, vin ...... CP) in follicular and mantle c

@en

P1433

Q33372106-1B29DBEB-3E40-4CA9-A1AD-E3D4ADBCA5F9

P1476

Q33372106-1C6433BA-0960-455A-A61F-253B20BDA453

P2093

Q33372106-091D86F8-BEB6-4B53-88F9-E3D0BF7714E2

Q33372106-15159E2B-5115-45F8-97AB-222D97849BE1

Q33372106-1A4855B2-97F4-4613-BD10-90FF5B3D520B

Q33372106-227983AE-9597-4944-BF10-E1E30598E50B

Q33372106-41402BD4-CA7A-4600-BAF9-3A4F06B82D38

Q33372106-4AF134C3-91CC-40E9-9106-626417301423

Q33372106-8D0C44CA-E934-4CAF-BD66-6C8EEFB5F105

Q33372106-E45B80F6-2BD5-4F93-9BF9-E2AACA017FA5

Q33372106-F5BB8F65-B1F2-47BE-80FD-A97105782946

P2860

Q33372106-D627E40D-ADB9-41EA-81EA-63A5968FCD8D

P304

Q33372106-76E93D2C-DF08-41EC-9E13-4289656C0AB2

P31

Q33372106-A2E0715E-7420-4AC1-93CF-4F88FB6ED128

P356

Q33372106-B10D2CB2-9E8A-4D15-A8D2-AE6F9B3AF960

P407

Q33372106-EC5DE1CC-EA07-45DF-9977-45979540FADE

P433

Q33372106-4C773D25-2CA0-418F-99E6-1202AE6B4B01

P478

Q33372106-8A33990C-E781-44E8-B14E-A7C315BAC6AB

P50

Q33372106-0635ABA2-77C6-4823-B98F-C71ED31B496E

Q33372106-EF3F2BC4-A236-4A23-8DF5-D175347767F4

P577

Q33372106-7628C845-B991-44AD-A884-C48E821015E7

P5875

Q33372106-25470EE8-953A-4A10-A1BD-D095E17C28BD

P698

Q33372106-4A98FF38-E1B1-4949-91D8-5F226623A6A5

P356

P1433

P1476

Combined cyclophosphamide, vin ...... CP) in follicular and mantle c

@en

P2093

Christina Nickenig

http://www.w3.org/2001/XMLSchema#string

Eva Lengfelder

http://www.w3.org/2001/XMLSchema#string

German Low-Grade Lymphoma Study Group

http://www.w3.org/2001/XMLSchema#string

Hannes Wandt

http://www.w3.org/2001/XMLSchema#string

Lorenz Trumper

http://www.w3.org/2001/XMLSchema#string

Marcel Reiser

http://www.w3.org/2001/XMLSchema#string

Martin Dreyling

http://www.w3.org/2001/XMLSchema#string

Michael Unterhalt

http://www.w3.org/2001/XMLSchema#string

Wolfgang Hiddemann

http://www.w3.org/2001/XMLSchema#string

P2860

Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab.

P304

1014-1022

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.22093

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Michael Pfreundschuh

P577

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6908946

http://www.w3.org/2001/XMLSchema#string

P698

16878325

http://www.w3.org/2001/XMLSchema#string